NuCana (NCNA) Interest Income - Net (2017 - 2025)
NuCana (NCNA) reported Interest Income - Net of -$17.0 million for Q4 2025, down 21670.29% on a YoY basis from N/an in Q4 2024, and down 8049.49% sequentially from -$209151.1 in Q3 2025.
NuCana (NCNA) Interest Income - Net (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Interest Income - Net data on file, last reported at -$17.0 million in Q4 2025.
- For the quarter ending Q4 2025, Interest Income - Net fell 21670.29% year-over-year to -$17.0 million; the trailing twelve-month figure through Dec 2025 stood at -$17.4 million (down 3715.75% YoY), and the FY2025 full-year result was -$17.2 million, down 3485.14% from the prior year.
- Interest Income - Net slipped to -$17.0 million in Q4 2025, from -$209151.1 in the prior quarter.
- In the past five years, Interest Income - Net ranged from a high of -$33700.3 in Q4 2021 to a low of -$17.0 million in Q4 2025.
- A 5-year average of -$1.2 million and a median of -$127545.6 in 2023 frame the typical range for Interest Income - Net.
- Across the five-year window, Interest Income - Net jumped 77.59% in 2021 and plunged 21670.29% in 2025, its largest moves.
- Tracing NCNA's Interest Income - Net over 5 years: stood at -$33700.3 in 2021, then slumped by 397.0% to -$167488.8 in 2022, then rose by 15.52% to -$141491.3 in 2023, then soared by 44.67% to -$78293.6 in 2024, then sank by 21670.29% to -$17.0 million in 2025.
- Business Quant data shows NCNA's Interest Income - Net at -$17.0 million in Q4 2025, -$209151.1 in Q3 2025, and -$78293.6 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Income - Net (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -17.04 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17.04 Mn |
| Sep 30, 2025 | -209,151.13 |
| Dec 31, 2024 | -78,293.61 |
| Sep 30, 2024 | -98,746.81 |
| Jun 30, 2024 | -113,599.87 |
| Mar 31, 2024 | -166,175.88 |
| Dec 31, 2023 | -141,491.31 |
| Sep 30, 2023 | -201,402.88 |
| Jun 30, 2023 | -232,753.55 |
| Mar 31, 2023 | -358,575.31 |
| Jun 30, 2022 | -167,488.79 |
| Mar 31, 2022 | -46,964.25 |
| Dec 31, 2021 | -33,700.27 |
| Sep 30, 2021 | -37,221.75 |
| Jun 30, 2021 | -54,511.40 |
| Mar 31, 2021 | -41,367.62 |
| Dec 31, 2020 | -23,768.12 |
| Sep 30, 2020 | -41,296.09 |
| Jun 30, 2020 | -79,468.52 |
| Mar 31, 2020 | -184,588.56 |